U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07190885) titled 'A Pharmacokinetic Study of YN001 in Healthy Participants' on Sept. 17.
Brief Summary: This is a Phase 1, single-center, open-label study designed to evaluate the pharmacokinetics (PK), safety, and immunogenicity following a single dose administration in healthy adult volunteers.
Study Start Date: Oct. 27
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: YN001
YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Beijing Inno Medicine Co., Ltd.
Published by HT Digital Content Services wit...